PakMediNet Discussion Forum : Medical Research in Pakistan : HCV treatment through miRNA
GlaxoSmithKline (GSK) has established a collaboration with Regulus Therapeutics to develop and commercialize therapeutics targeting microRNA-122 for hepatitis C virus (HCV) infection. Although a clinical development candidate has yet to be identified, recent findings in non-human primates indicate that targeting microRNA-122 blocks HCV replication and could offer advantages over current HCV therapies (Science 327, 198–201; 2010).
Best regards
aftab
Posted by: aftabac Posts: 271 :: 01-05-2010 :: | Reply to this Message